Clinical trials: Prostate Cancer Stage I
- Condition Prostate Cancer Stage I
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostatic Neoplasms
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
- Trial name
- NCT00121095
- Testing
- Samarium Sm-153 lexidronam + Docetaxel
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cytogen Corporation
Prostate Cancer
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer.
- Trial name
- NCT00116155
- Testing
- CV787 (CG7870)
- Sponsor
- Cell Genesys
Prostatic Neoplasms
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
The primary objective of this study was to determine the safety and Maximum tolerated dose (MTD) of BIBF 1120 combination therapy with docetaxel and prednisone in patients with hormone refractory prostate cancer.
- Trial name
- NCT02182219
- Testing
- BIBF 1120
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer.
- Trial name
- NCT01048151
- Testing
- TNFerade™ Biologic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GenVec
Prostate Cancer
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer.
- Trial name
- NCT00895466
- Testing
- PEP-223/CoVaccine HT
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Pepscan Therapeutics
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.